Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Abroad (travel likely)RecruitingPHASE3

Conditions

Nasopharyngeal Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Ming-Yuan Chen, MD,PhD) · chmingy@mail.sysu.edu.cn · 86-20-8734-2422
Contact: Study coordinator (Rui You, MD,PhD) · yourui@sysucc.org.cn · +8613580439820

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma (NPC)

Abroad (travel likely)RecruitingPHASE3

Nanning, China

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Fuzhou, China · Xiamen, China

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China · Guangzhou, China

Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China